- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002011
The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex
June 23, 2005 updated by: Mallinckrodt
To determine the safety and patient tolerance of UVAR Photopheresis System (extracorporeal photopheresis) in the Treatment of AIDS-Related Complex (ARC).
Study Overview
Detailed Description
Treatment involves the patient ingesting 8-methoxsalen (8-MOP) by mouth approximately two hours prior to each photopheresis session.
The photopheresis instrument will separate the patient's white blood cells and some plasma from other blood components and return the majority of blood components to the patient.
The separated white blood cells and plasma will be exposed to UVA (Ultraviolet A) light while outside the body.
The UVA light photoactivates the 8-MOP drug which is now located in the DNA of the collected cells.
After this exposure, the patients photoactivated white blood cells will be returned to the patient by venous access.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Morristown, New Jersey, United States, 07962
- Morristown Memorial Hosp
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
Patients must have the following:
- Diagnosis of AIDS-related complex (ARC).
- Veins that can provide adequate access.
- Negative drug screen for drugs of abuse and zidovudine (AZT).
- Be willing to adhere to the protocol and sign a patient informed consent prior to study entry.
- Live within adequate commuting distance to the treatment center.
- Not be on any other investigational drug/device.
- Be 18 - 80 years old but minimum age requirements may be affected by state regulations or specific medical conditions.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Inability to tolerate extracorporeal volume loss during the leukocyte-enrichment phase.
- Photosensitive disease, such as porphyria or systemic lupus erythematosus. Care must be taken in selecting patients who require drugs (either systemically or topically) during the course of the study with photosensitizing potential such as phenothiazines, tetracyclines, sulfonamides or chlorothiazide.
- Renal insufficiency with creatinine > 3 mg/dl.
- Symptoms of toxic effects (World Health Organization Criteria) resulting from previous therapy.
- Severe emotional, behavioral or psychiatric problems that in the opinion of the investigator would result in poor compliance with the treatment regimen.
- Idiosyncratic or hypersensitivity reactions to 8-MOP compounds.
- History of or active Pneumocystis carinii pneumonia, other opportunistic infection or neoplasms (Kaposi's sarcoma), or wasting syndrome.
- Active hepatitis.
- Aphakia because of the significantly increased risk of retinal damage due to absence of lenses.
Concurrent Medication:
Excluded:
- Zidovudine (AZT).
- Photosensitizing drugs should not be administered prior to photopheresis treatment.
- Other investigational drugs.
Concurrent Treatment:
Excluded:
- Other treatment using an investigational device.
Patients with the following are excluded:
- Inability to tolerate extracorporeal volume loss during the leukocyte-enrichment phase.
- Photosensitive disease.
- Symptoms of toxic effects (World Health Organization Criteria) resulting from previous therapy.
- Severe emotional, behavioral or psychiatric problems that in the opinion of the investigator would result in poor compliance with the treatment regimen.
- Idiosyncratic or hypersensitivity reactions to 8-MOP compounds.
- Actively involved in drug abuse.
- Aphakia because of the significantly increased risk of retinal damage due to absence of lenses.
Prior Medication:
Excluded:
- Zidovudine (AZT).
Actively involved in drug abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 2, 1999
First Submitted That Met QC Criteria
August 30, 2001
First Posted (Estimate)
August 31, 2001
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
July 1, 1990
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- AIDS-Related Complex
- Photosensitizing Agents
- Dermatologic Agents
- Methoxsalen
Other Study ID Numbers
- 049A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Methoxsalen
-
National Center for Research Resources (NCRR)Northwestern UniversityCompletedEpidermolysis Bullosa Acquisita
-
Central Hospital, Nancy, FranceUnknown
-
M.D. Anderson Cancer CenterUniversity of Pittsburgh; Rush University Medical Center; Boston Medical Center; Vanderbilt University Medical Center and other collaboratorsCompletedMycosis Fungoides | Cutaneous T Cell LymphomaUnited States
-
MallinckrodtICON plcCompletedCrohn's DiseaseBelgium, Germany, United States, Austria
-
MillennixUnknownLymphomaUnited States
-
Oleg E. Akilov, MD, PhDMallinckrodtRecruiting
-
Hospices Civils de LyonUnknown
-
MallinckrodtCompletedGraft-versus-Host DiseaseUnited States, Australia, United Kingdom, Slovakia, Brazil, Germany, Italy, Portugal, Turkey
-
MallinckrodtCompletedGraft-versus-Host DiseaseUnited States, Australia, France, Italy, Austria, Germany, Portugal, Slovakia, Spain, Switzerland, Turkey, United Kingdom
-
MallinckrodtParexelCompletedChronic Graft Versus Host DiseaseUnited States, France, Germany, United Kingdom, Spain, Italy, Austria, Hungary